Homepage
Medication Guide
Precautions for Zolbetuximab
As an IgG1 monoclonal antibody targeting Claudin 18.2 (CLDN18.2), zolbetuximab plays a crucial role in the treatment of advanced or metastatic gastric cancer positive for CLDN18.2. The process of prep...
506
Monday, September 1st, 2025, 13:53
What is the Price of Zolbetuximab?
Zolbetuximab is a targeted therapeutic drug directed against CLDN18.2, and it has attracted significant attention in the field of gastric cancer treatment. It has been launched in China but is not inc...
510
Monday, September 1st, 2025, 13:48
How to Purchase Zolbetuximab
Zolbetuximab is a targeted therapeutic drug against CLDN18.2, which plays a crucial role in the treatment of unresectable, advanced, and recurrent gastric cancer positive for Claudin18.2. Its unique t...
520
Monday, September 1st, 2025, 13:38
Is Zolbetuximab Available for Purchase in China?
Zolbetuximab demonstrates favorable efficacy in the treatment of unresectable advanced recurrent gastric cancer positive for Claudin 18.2 (CLDN18.2). For many patients, whether zolbetuximab can be pur...
511
Monday, September 1st, 2025, 13:11
Latest Price of Zolbetuximab in 2025
Zolbetuximab, also known by the alias claudixmab, is a targeted therapeutic drug against CLDN18.2, and it has shown significant potential in the treatment of gastric cancer. With the arrival of 2025, ...
522
Monday, September 1st, 2025, 13:07
How Much Does Zolbetuximab Cost?
Zolbetuximab is a synthetic IgG1 monoclonal antibody drug targeting Claudin 18.2 (CLDN18.2). It has demonstrated significant efficacy in the treatment of unresectable advanced recurrent gastric cancer...
529
Monday, September 1st, 2025, 11:58
Zolbetuximab: Clinical Uses, Recommended Dosage, Potential Side Effects
Zolbetuximab (brand name: VYLOY) is a cytolytic antibody targeting Claudin 18.2 (CLDN18.2). It was first approved for marketing in the United States in 2024. It is indicated for the first-line treatme...
518
Monday, September 1st, 2025, 11:51
Recommended Dosage and Administration of Zolbetuximab
Zolbetuximab (trade name: VYLOY) is a cytolytic antibody-drug targeting Claudin 18.2 (CLDN18.2). It was first approved for marketing in the United States in 2024. This drug is indicated as first-line ...
526
Monday, September 1st, 2025, 11:39
Main Adverse Reactions of Zolbetuximab
As a cytolytic antibody-drug targeting Claudin 18.2, zolbetuximab is used in the treatment of HER2-negative, CLDN18.2-positive locally advanced unresectable or metastatic adenocarcinoma of the stomach...
533
Monday, September 1st, 2025, 11:31
Precautions for Zolbetuximab
Although zolbetuximab has demonstrated efficacy in clinical trials, there are several warnings and precautions that require close attention during its use. The relevant information is detailed below.P...
514
Monday, September 1st, 2025, 11:17
142 / 215
2145 in total
Departments
Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
haiousales@gmail.com
Welcome To Consult
Seagull Pharmacy.,Ltd All rights reserved